50837-53-1

Basic information

• Product Name: 2,5-DIMETHYLBENZYL BROMIDE
• Synonyms: 2,5-DIMETHYLBENZYL BROMIDE;2,5-Dimethylbenzylbromid;2-(bromomethyl)-1,4-dimethylbenzene;Benzene,2-(bromomethyl)-1,4-dimethyl-;DHJPEGRMZQBUMM-UHFFFAOYSA-N
• CAS NO: 50837-53-1
• Molecular Formula: C₉H₁₁Br
• Molecular Weight: 199.09
• Mol File: 50837-53-1.mol

Chemical Properties

• Boiling Point: 233.837°C at 760 mmHg
• Flash Point: 100.583°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 0.083mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 2,5-DIMETHYLBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYLBENZYL BROMIDE(50837-53-1)
• EPA Substance Registry System: 2,5-DIMETHYLBENZYL BROMIDE(50837-53-1)

Safety Data

• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 3265
• Hazardous Substances Data: 50837-53-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYLBENZYL BROMIDE is used as a reagent in organic synthesis for the production of pharmaceuticals, contributing to the development of new medications and improving existing ones.
Used in Fine Chemicals Industry:
2,5-DIMETHYLBENZYL BROMIDE is used as a reagent in the synthesis of fine chemicals, which are high-purity chemicals used in various applications, including research, diagnostics, and specialty manufacturing.
Used in Flavors and Fragrances Industry:
2,5-DIMETHYLBENZYL BROMIDE is used as an intermediate in the manufacturing of flavors and fragrances, enhancing the sensory properties of various consumer products.
Used in Organic Synthesis:
2,5-DIMETHYLBENZYL BROMIDE is used as a reagent in organic synthesis for the production of various compounds, enabling the creation of new materials and substances with specific properties and applications.

InChI:InChI=1/C9H11Br/c1-7-3-4-8(2)9(5-7)6-10/h3-5H,6H2,1-2H3

Upstream product

• 5779-94-2 2,5-dimethylbenzaldehyde 
• 50-00-0 formaldehyd 
• 106-42-3 para-xylene 
• 53957-33-8 2,5-dimethylbenzyl alcohol 

Downstream Products

• 1053745-50-8 N-{(2R,3R,3aS,9aR)-2-[6-(2,5-Dimethyl-benzylamino)-purin-9-yl]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-yl}-3-methoxy-benzamide 
• 1351646-50-8 4-[1-(2,5-dimethylbenzyl)-4-methoxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid 
• 109936-71-2 N-acetyl-2-ethoxycarbonyl-3-(2,5-dimethylphenyl)-α-alanine ethyl ester 
• 69299-47-4 3,4-Dimethyl-5<2,5-dimethyl-phenyl>-isoxazol 
• 37765-73-4 (2,5-dimethyl-benzyl)-malonic acid diethyl ester 
• 59275-44-4 1-(2,5-dimethyl-benzyl)-2-(2-methyl-[1,3]dioxolan-2-yl)-pyridinium; bromide 
• 13612-34-5 2-(2,5-dimethylphenyl)acetic acid 
• 6972-51-6 2-(2,5-dimethylphenyl)ethan-1-ol 
• 1090896-82-4 3-[3-(2,5-dimethyl-benzyl)-2-oxo-2,3-dihydro-benzoimidazol-1-yl]-hexanoic acid 
• 161865-25-4 2-(but-3-enyl)-1,4-dimethylbenzene 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AS PERK INHIBITORS

The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis of 2,2-dimethyl-3-(3-methyl phenyl)propanal and its derivatives

An alternative approach to the synthesis of 2,2-dimethyl-3-(3-methylphenyl) propanal and its derivatives was described. 2,2-Dimethyl-3-(3-methylphenyl) propanal and its derivatives were obtained in middle yields from various substituted alkylaromtics, via bromination and alkylation. Its feature of fragrance was green, reminiscent of leaves, with flowery-aldehydic aspects. Copyright

Bromomethylation of aromatics mediated by low frequency ultrasound

We report herein bromomethylation of aromatics mediated by low frequency ultrasound to yield bromomethylated aromatic rings which are useful synthetic intermediates.